DelveInsight’s 'Complement Inhibitors Pipeline Insight 2024' report provides comprehensive global coverage of pipeline complement inhibitors in various stages of clinical development, major ...
“The whole is greater than the sum of its parts.” — Aristotle Figure 1: Complement-mediated intracellular and autocrine regulation of the activation of CD4 + T cells. The studies noted above have ...
(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback